Fox Run Management L.L.C. Takes $210,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Fox Run Management L.L.C. acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 31,078 shares of the company’s stock, valued at approximately $210,000.

A number of other institutional investors also recently bought and sold shares of the stock. KLP Kapitalforvaltning AS purchased a new stake in Recursion Pharmaceuticals in the fourth quarter worth about $346,000. Plancorp LLC increased its holdings in Recursion Pharmaceuticals by 12.9% in the 4th quarter. Plancorp LLC now owns 87,584 shares of the company’s stock worth $592,000 after acquiring an additional 10,000 shares in the last quarter. Teacher Retirement System of Texas raised its stake in Recursion Pharmaceuticals by 60.0% during the 4th quarter. Teacher Retirement System of Texas now owns 73,392 shares of the company’s stock worth $496,000 after acquiring an additional 27,511 shares during the period. Privium Fund Management B.V. lifted its holdings in Recursion Pharmaceuticals by 52.6% during the fourth quarter. Privium Fund Management B.V. now owns 119,000 shares of the company’s stock valued at $804,000 after purchasing an additional 41,000 shares in the last quarter. Finally, Platinum Investment Management Ltd. boosted its position in shares of Recursion Pharmaceuticals by 293.9% in the fourth quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company’s stock worth $4,955,000 after purchasing an additional 546,929 shares during the period. 89.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of analyst reports. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Trading Down 2.7 %

Shares of Recursion Pharmaceuticals stock opened at $5.81 on Friday. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -3.80 and a beta of 0.85. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $12.36. The business has a 50-day moving average price of $7.44 and a 200-day moving average price of $7.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business’s revenue was down 57.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.42) EPS. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.